ALZN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALZN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Alzamend Neuro's basic earnings per share (Basic EPS) for the three months ended in Jul. 2024 was $-1.25. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jul. 2024 was $-10.69.
Alzamend Neuro's EPS (Diluted) for the three months ended in Jul. 2024 was $-1.25. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jul. 2024 was $-10.69.
Alzamend Neuro's EPS without NRI for the three months ended in Jul. 2024 was $-1.25. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jul. 2024 was -10.69.
During the past 3 years, the average EPS without NRI Growth Rate was -153.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was -107.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 6 years, Alzamend Neuro's highest 3-Year average EPS without NRI Growth Rate was -36.70% per year. The lowest was -214.30% per year. And the median was -153.50% per year.
The historical data trend for Alzamend Neuro's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alzamend Neuro Annual Data | |||||||||||||||
Trend | Apr19 | Apr20 | Apr21 | Apr22 | Apr23 | Apr24 | |||||||||
EPS (Basic) | Get a 7-Day Free Trial | -7.37 | -8.91 | -21.00 | -228.90 | -147.00 |
Alzamend Neuro Quarterly Data | ||||||||||||||||||||
Apr19 | Jan20 | Apr20 | Jul20 | Oct20 | Jan21 | Apr21 | Jul21 | Oct21 | Jan22 | Apr22 | Jul22 | Oct22 | Jan23 | Apr23 | Jul23 | Oct23 | Jan24 | Apr24 | Jul24 | |
EPS (Basic) | Get a 7-Day Free Trial | -5.38 | -4.40 | -3.80 | -1.24 | -1.25 |
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Alzamend Neuro's Basic EPS for the fiscal year that ended in Apr. 2024 is calculated as
Basic EPS (A: Apr. 2024 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Basic Average) |
= | (-9.948 | - | 0) | / | 0.068 | |
= | -146.29 |
Alzamend Neuro's Basic EPS for the quarter that ended in Jul. 2024 is calculated as
Basic EPS (Q: Jul. 2024 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Basic Average) |
= | (-0.974 | - | 0) | / | 0.778 | |
= | -1.25 |
EPS (Basic) for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.69
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alzamend Neuro (NAS:ALZN) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Alzamend Neuro's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.
Ault Milton C Iii | 10 percent owner | 11411 SOUTHERN HIGHLANDS PARKWAY, SUITE 240, LAS VEGAS NV 89141 |
David J Katzoff | officer: Chief Operating Officer | 201 SHIPYARD WAY, NEWPORT BEACH CA 92663 |
Stephan Jackman | director, officer: Chief Executive Officer | C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612 |
Lynne Fahey Mcgrath | director | 28145 CEDAR POINT RD., EASTON MD 21601 |
Mark Gustafson | director | 10691 ROSECROFT CRESCENT, RICHMOND A1 V7A 2H9 |
William B. Horne | director | C/O AULT ALLIANCE, INC., 940 SOUTH COAST DRIVE, SUITE 200, COSTA MESA CA 92626 |
Henry Carl Nisser | director, officer: Exec VP and General Counsel | 100 PARK AVENUE, SUITE 1658A, NEW YORK NY 10017 |
Kenneth S Cragun | officer: SVP of Finance | 3775 CHIPPEWA CIRCLE, CORONA CA 92881 |
Jeffrey Oram | director | 15 ORCHARD STREET, MENDHAM NJ 07945 |
Escalona Lien | officer: Chief Financial Officer | C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612 |
Andrew H. Woo | director | 2021 SANTA MONICA BLVD., SUITE 525E, SANTA MONICA CA 90404 |
From GuruFocus
By Business Wire Business Wire • 11-15-2022
By Business Wire • 05-22-2024
By Business Wire Business Wire • 06-13-2023
By Business Wire • 10-30-2023
By Business Wire • 05-14-2024
By Business Wire • 12-11-2023
By Business Wire Business Wire • 03-22-2023
By Business Wire Business Wire • 12-28-2022
By Business Wire • 07-31-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.